Related by context. All words. (Click for frequent words.) 71 PXD# 70 HGS ETR1 69 enzastaurin 68 Azedra 68 elotuzumab 68 eniluracil 68 alvespimycin 68 Marqibo 68 IMC A# 67 phase IIb clinical 67 tanespimycin 67 ganetespib 67 AP# [003] 67 MGCD# [001] 67 JAK inhibitor 66 HGS ETR2 66 sapacitabine 66 Panzem R NCD 66 obatoclax 66 glufosfamide 66 Phase Ib 66 Onco TCS 66 INCB# [001] 66 Nanobody 66 picoplatin 66 rNAPc2 66 AQ4N 66 Targretin 66 apaziquone 66 CR# vcMMAE 66 TACI Ig 66 Pimavanserin 65 Phase Ib study 65 tiapamil 65 investigational compounds 65 Bicifadine 65 HER2 positive metastatic breast 65 epothilone 65 tesetaxel 65 Amigal 65 Amrubicin 65 registrational 65 FOLOTYN ® 65 INCB# [002] 65 Alocrest 65 zanolimumab 65 TREANDA 65 Sym# 65 BAY #-# 65 oral prodrug 65 YONDELIS 65 ponatinib 65 FOLOTYN 65 dacetuzumab 65 MDV# 65 HuMax CD4 65 HspE7 65 perifosine 65 ZEVALIN 65 blinatumomab 65 panitumumab 65 PDE4 inhibitor 65 mapatumumab 64 pomalidomide 64 cancer immunotherapies 64 ELACYT 64 cilengitide 64 Symadex 64 AEG# 64 ATL# [001] 64 PEG SN# 64 ofatumumab 64 cangrelor 64 huC# DM4 64 HGS# 64 cetuximab Erbitux R 64 OvaRex ® MAb 64 Allovectin 7 64 lintuzumab 64 otelixizumab 64 tesmilifene 64 vandetanib 64 XmAb# 64 valopicitabine 64 CD# antibody [001] 64 pralatrexate 64 histone deacetylase HDAC inhibitor 64 EOquin 64 custirsen 64 voreloxin 64 Phase Ib II 64 forodesine 64 TELINTRA 64 phase IIb 64 pertuzumab 64 TYZEKA 64 decitabine 64 registrational trial 64 pan HDAC inhibitor 64 deforolimus 64 EOquin TM 64 Triolex 64 HuMax CD# 64 TOCOSOL Paclitaxel 64 celgosivir 64 vosaroxin 64 Bezielle 63 ixabepilone 63 MGd 63 IMA# 63 CYC# 63 radiation sensitizer 63 Rebif ® 63 velafermin belinostat 63 myeloproliferative disorders 63 bevacizumab Avastin ® 63 OvaRex R 63 subcutaneous formulation 63 Asentar 63 TELCYTA 63 methylnaltrexone 63 OXi# 63 Dacogen injection 63 omacetaxine 63 Archexin 63 vorinostat 63 axitinib 63 GRN#L 63 CA4P 63 RG# [001] 63 dasatinib Sprycel ® 63 palifosfamide 63 atacicept 63 thymalfasin 63 romidepsin 63 CoFactor 63 Neuradiab 63 L BLP# 63 CD# monoclonal antibody 63 investigational monoclonal antibody 63 sorafenib Nexavar 63 CBLC# 63 relapsed multiple myeloma 63 DAVANAT 63 phase IIa clinical 63 IAP inhibitors 63 Hsp# inhibitor 62 Phase 2b study 62 RGB # 62 T DM1 62 ISTODAX 62 Carfilzomib 62 Perifosine 62 ALN PCS 62 indibulin 62 bafetinib 62 daclizumab 62 Annamycin 62 XL# [003] 62 Xanafide 62 DXL# 62 HCV protease inhibitor 62 AeroLEF TM 62 receptor tyrosine kinase inhibitor 62 EndoTAG TM -1 62 Phase 2b clinical 62 Phase IIa clinical 62 DOS# 62 IL# PE#QQR 62 investigational humanized monoclonal antibody 62 Nanobody ® 62 orally administered inhibitor 62 TBC# 62 Allovectin 7 R 62 cell lymphoma CTCL 62 Azixa 62 IMGN# 62 bendamustine 62 Tesetaxel 62 Traficet EN 62 Proxinium TM 62 MKC# MT 62 Belinostat 62 Phase IIa trials 62 elacytarabine 62 myelofibrosis polycythemia vera 62 ZEVALIN ® 62 LEUKINE 62 AEGR 62 Urocidin 62 TG# [003] 62 Factor VIIa 62 ISIS # 62 OncoVEX GM CSF 62 tezampanel NGX# 62 PRT# 62 PLK1 SNALP 62 Ceflatonin 62 phase 2a 62 gefitinib Iressa 62 HDAC Inhibitor 62 Phase Ib clinical 62 IRX 2 62 Laquinimod 62 Plicera 62 Zolinza 62 PEG Interferon lambda 62 dose cohorts 62 Tavocept 62 ELND# 62 lumiliximab 62 Vilazodone 62 REOLYSIN ® 62 FUSILEV ® 62 Virulizin ® 62 JAK1 62 anticancer agents 62 GRNVAC1 62 Phase Ib clinical trials 62 phenoxodiol 62 LY# [003] 62 humanized anti 62 NGX# 62 HuMax EGFr 62 Synavive 62 Neulasta ® 62 oral ridaforolimus 62 bardoxolone 62 erlotinib Tarceva 62 GAP #B# 62 hematological cancers 62 RSD# oral 62 Azedra TM 61 vemurafenib 61 mertansine 61 ZYBRESTAT 61 MYDICAR ® 61 MNTX 61 Aurexis 61 imetelstat 61 PNP inhibitor 61 SUTENT 61 velafermin 61 Stedivaze 61 Nuvion 61 Insegia 61 Personalized Immunotherapy 61 SCH # 61 KRN# 61 Imprime PGG 61 ularitide 61 ofatumumab HuMax CD# 61 Troxatyl 61 docetaxel Taxotere R 61 PRECISE trial 61 liposomal formulation 61 EndoTAG 61 APOPTONE 61 CD# CEA 61 Pralatrexate 61 Aflibercept 61 PS# [001] 61 Exelixis compounds 61 leading oral taxane 61 multi kinase inhibitor 61 PrevOnco 61 cannabinor 61 hematologic malignancies 61 Phase IIb trials 61 Corlux 61 pradefovir 61 Daclizumab 61 IMC #B 61 Chemophase 61 ONTAK 61 Resten NG 61 IV Busulfex 61 EFAPROXYN 61 preclinically 61 dirucotide 61 MAGE A3 ASCI 61 Treanda 61 Cloretazine ® 61 ASA# 61 proteasome inhibitor 61 phase IIb trial 61 depsipeptide 61 Phase 2b trial 61 octreotide implant 61 PF # [001] 61 posaconazole 61 Myocet 61 orally bioavailable 61 Viprinex 61 ThermoDox R 61 epigenetic therapies 61 CYT# 61 metastatic renal cell carcinoma 61 sodium thiosulfate STS 61 NP2 Enkephalin 61 Civacir 61 ADVEXIN 61 talactoferrin 61 Ozarelix 61 investigational antiplatelet agent 61 MEK inhibitor RDEA# 61 AAG geldanamycin analog 61 MCSP respectively 61 ridaforolimus 61 veltuzumab 61 hematological malignancies 61 Targeted Chemotherapy 61 ruxolitinib 61 HuLuc# 61 Phase 2a trial 61 selective androgen receptor modulator 61 elesclomol 61 Celator 61 dalbavancin 61 Bortezomib 61 Æterna Zentaris 61 Aurora kinase 61 BCX# 61 MEK inhibitors 61 metastatic hormone refractory 61 SAR# [004] 61 tezampanel 61 Amplimexon 61 NNR Therapeutics 61 vidofludimus 61 teduglutide 61 rALLy clinical trial 61 LEP ETU 61 MyVax R 60 JAK inhibitors 60 castrate resistant prostate cancer 60 Cleviprex TM clevidipine 60 synthetic retinoid 60 XL# XL# XL# 60 Tyrima 60 PDX pralatrexate 60 Viramidine 60 metaglidasen 60 Lixivaptan 60 SinuNase 60 zalutumumab 60 confirmatory Phase III 60 Theratope 60 virus HCV protease inhibitor 60 tyrosine kinase inhibitor 60 Clolar ® 60 PSMA ADC 60 TAFA# 60 TKB# 60 vilazodone 60 ZOLINZA 60 cutaneous T cell 60 ceftaroline 60 ENMD # 60 Genasense 60 ocrelizumab 60 Capesaris 60 Phase #b/#a clinical 60 preclinical compounds 60 INTEGRILIN 60 neratinib 60 Dapagliflozin 60 anticancer compounds 60 metastatic castration resistant 60 CINTREDEKIN BESUDOTOX 60 TRV# [001] 60 IAP inhibitor 60 PANVAC VF 60 DAVANAT R 60 Onalta 60 Phase 1b 60 TRIOLEX 60 including eniluracil ADH 60 albinterferon alfa 2b 60 erlotinib Tarceva ® 60 targeted radiotherapeutic 60 docetaxel Taxotere ® 60 Taxotere ® 60 bicifadine 60 ProLindac 60 CANCIDAS 60 XmAb ® 60 sunitinib malate 60 Pazopanib 60 PI3K/Akt pathway inhibitor 60 regorafenib 60 Cetrorelix 60 refractory AML 60 carfilzomib 60 Zybrestat 60 polymerase inhibitors 60 Alfimeprase 60 seliciclib 60 lesinurad 60 Phase 1b trial 60 vinorelbine 60 Velcade bortezomib 60 #I TM# 60 Solazed TM 60 Mipomersen 60 hypoxia activated prodrug 60 ALN TTR# 60 galiximab 60 Vectibix panitumumab 60 Glufosfamide 60 anticancer agent 60 danoprevir 60 JAK2 inhibitors 60 humanized monoclonal antibody 60 SARMs 60 oncology therapeutics 60 castration resistant prostate cancer 60 Phase IIa trial 60 Virulizin R 60 DPX Survivac 60 MEK inhibitor 60 aflibercept 60 nicotinic alpha 7 60 LymphoStat B 60 Pivotal Phase III 60 refractory gout 60 BioNumerik 60 angiogenesis inhibitor 60 Tezampanel 60 LibiGel ® 60 myelofibrosis 60 RhuDex ® 60 anticancer compound 60 PEP# [003] 60 CRx 60 adecatumumab MT# 60 cetuximab Erbitux ® 60 ulimorelin 60 dextromethorphan quinidine 60 seliciclib CYC# 60 ozarelix 60 JAK2 inhibitor 60 telomerase therapeutic 60 nitazoxanide 60 phase Ib 60 CEQ# 60 DermaVir Patch 60 Squalamine 60 Preclinical studies suggest 60 Leukine 60 trastuzumab DM1 T DM1 60 triphendiol 60 Clonicel 60 SinuNase ™ 60 PLX# 60 IgG1 monoclonal antibody 60 evaluating tivozanib 60 lintuzumab SGN 60 Phase IIIb clinical 60 afatinib 60 Omacetaxine 60 NVA# 60 Zenvia ™ 60 lupus nephritis 59 docetaxel chemotherapy 59 AKT inhibitor 59 Evoltra ® 59 R#/MEM # 59 NXL# 59 ARIKACE ™ 59 Clavis Pharma 59 lymphoma CTCL 59 brivaracetam 59 immunomodulator 59 KNS # 59 Æterna Zentaris Inc. 59 CD3 monoclonal antibody 59 trastuzumab Herceptin R 59 PROSTVAC TM 59 Exherin TM 59 indolent NHL 59 Homspera 59 Onconase 59 BIBW 59 RIGScan CR 59 eprotirome 59 Harry Palmin President 59 DU #b 59 Elagolix 59 Phase IIB 59 Fludara ® 59 randomized Phase 2b 59 HQK 59 adipiplon 59 elvucitabine 59 histone deacetylase inhibitor 59 MOZOBIL 59 pharmacodynamic profile 59 gemcitabine Gemzar ® 59 CYT# potent vascular disrupting 59 Nexavar ® 59 AVE# 59 PI3K inhibitor 59 Curaxin 59 HRPC 59 mRCC 59 Apoptone 59 lorvotuzumab mertansine 59 CRMD# 59 oral deforolimus 59 initiated Phase 1b 59 Romidepsin 59 pharmacokinetic PK study 59 Vidaza 59 gefitinib 59 protein kinase inhibitor 59 GED aPC 59 INT# [002] 59 PHX# 59 Sapacitabine 59 Marqibo TM 59 PCK# 59 APD# 59 targeting CD# 59 Phase IIa clinical trials 59 Phase III clinical 59 PRTX 59 anti leukemic 59 tramiprosate 59 Tarceva TM 59 Exelixis XL# 59 double blinded placebo 59 selective kinase inhibitor 59 faropenem 59 mGluR5 negative 59 vascular disrupting agents 59 Seliciclib 59 CDK inhibitor 59 XL# XL# 59 oral taxane 59 dacarbazine 59 bortezomib Velcade R 59 PSN# [002] 59 Epratuzumab 59 pharmacokinetic PK 59 Blinatumomab 59 Tasimelteon 59 Trastuzumab 59 pegloticase 59 davunetide intranasal AL 59 solid tumors 59 Vandetanib 59 THALOMID 59 phase IIa 59 Debio 59 dasatinib 59 dexpramipexole 59 ENMD 59 ADI PEG 59 vicriviroc 59 Ocrelizumab 59 Intarcia 59 ALN HPN 59 Jevtana 59 midstage clinical 59 AEZS 59 BRAF inhibitor 59 AzaSite Plus 59 varespladib 59 multicenter Phase 59 satraplatin 59 entinostat 59 refractory multiple myeloma 59 GAMMAGARD 59 Altastaph 59 reslizumab 59 Chrysalin 59 novel peptide 59 ARRY 59 OHR/AVR# 59 lapatinib Tykerb 59 Atiprimod 59 trabedersen 59 nab paclitaxel 59 Nexavar sorafenib 59 XL# XL# XL# XL# 59 Xcytrin R 59 trabectedin 59 budiodarone 59 elinogrel 59 amrubicin 59 AZD# 59 VitiGam 59 Golimumab 59 MEND CABG II 59 SLx 59 linaclotide 59 tecarfarin 59 Androxal TM 59 antisense drug 59 PROSTVAC VF 59 MAb 59 darinaparsin 59 ALN TTR 59 standard chemotherapy regimen 59 isoform selective 59 Zingo TM 59 carboplatin paclitaxel 59 PRX # 59 Vidaza R 59 mipomersen 59 Phase IIb clinical 59 antibody MAb 59 cediranib 59 adecatumumab 59 goserelin 59 Cethrin 59 dimebon 59 ISENTRESS 59 PEG PAL 59 R roscovitine 59 VQD 59 Innovive 59 FLT3 59 Albuferon 59 GV# [001] 59 tamibarotene 59 budesonide foam 59 hormone refractory prostate cancer 59 SAR# [002] 59 chemotherapeutic agents 59 Tanespimycin 59 relapsed refractory 59 Veronate 59 anidulafungin 59 AGILECT R 59 Sudhir Agrawal D.Phil 59 RECOTHROM R 59 Aplidin 59 microtubule inhibitor 59 antibody MT# 59 Fibrin Pad 59 subcutaneously administered 59 TRO# 59 dose escalation 59 ospemifene 59 leukemia AML 59 SinuNase TM 59 ASONEP 59 nimotuzumab 59 Dalbavancin 59 BAL# [002] 59 huN# DM1 59 relapsed refractory multiple myeloma 59 Panzem R 59 MT# MEDI 59 radezolid 59 Cloretazine 59 SCCHN 59 Serdaxin 59 GVAX 59 FavId 59 anticancer therapies 59 ZACTIMA 59 nucleoside analog 59 VAPRISOL 59 CORT # 59 Solazed 59 trastuzumab Herceptin 59 APTIVUS r 59 RSD# 59 Hsp# inhibitors 59 Shigamabs ® 58 ALN VSP 58 vascular disrupting agent 58 nucleoside 58 AGGRASTAT R 58 Luteinizing Hormone Releasing Hormone 58 azacitidine 58 ibudilast 58 selective modulator 58 epothilones 58 generation purine nucleoside 58 OPAXIO 58 dosing regimens 58 recurrent glioblastoma 58 lymphoid malignancies 58 Desmoteplase 58 therapeutic monoclonal antibodies 58 DR Cysteamine 58 pralatrexate injection 58 mitomycin 58 investigational therapies 58 BRIM2 58 registrational studies 58 voclosporin 58 SUPPRELIN R LA 58 Neurodex 58 platelet inhibitor 58 endocrine therapy 58 T Pred 58 Phase IIb clinical trials 58 OMP #R# 58 Excellagen 58 Leukine ® 58 PDE# inhibitors 58 Phase #b/#a 58 imatinib resistant 58 RAV# 58 DDP# 58 oblimersen 58 MKC# MKC# PP 58 pharmacokinetics pharmacodynamics 58 R#/MEM 58 humanized antibodies 58 trastuzumab DM1 58 EndoTAGTM 1 58 sargramostim 58 Radezolid 58 Revlimid lenalidomide 58 ecallantide 58 Voreloxin 58 cetuximab Erbitux 58 GMX# 58 Icatibant 58 randomized controlled Phase 58 oral antiviral 58 rituximab Rituxan ® 58 Prestara 58 OncoVEX 58 NSCLC 58 novel VDA molecule 58 Intravenous CP 58 mTOR inhibitor 58 evaluating REVLIMID 58 bortezomib Velcade 58 JZP 58 CTCE 58 initiated Phase Ib 58 midstage studies 58 pexiganan 58 imatinib Gleevec 58 Stimuvax R 58 glatiramer acetate 58 multitargeted 58 HCD# [002] 58 TroVax 58 direct thrombin inhibitors 58 docetaxel 58 Nasulin 58 GALNS 58 Ostarine 58 Fludara 58 Irinotecan 58 IMiDs 58 SPRYCEL ® 58 Spiro Rombotis President 58 Prodarsan ® 58 PrevOnco ™ 58 thalidomide Thalomid 58 CytoFabTM 58 Gleevec imatinib mesylate 58 rHuPH# 58 Vaccinex 58 Mitoxantrone 58 ZYBRESTAT TM 58 Restanza 58 eculizumab 58 initiate Phase 1b 58 interferon gamma 1b 58 Advexin 58 drug conjugate 58 RDEA# 58 luteinizing hormone releasing 58 ACTEMRA TM 58 LymphoStat B belimumab 58 dosing cohorts 58 pharmacodynamic markers 58 bevacizumab Avastin R 58 Phase 2b 58 Ceflatonin R 58 CDP# 58 tivozanib 58 kinase inhibition 58 CCR9 antagonist 58 Phase III randomized controlled 58 LymphoStat B TM 58 Guanilib 58 metastatic sarcomas 58 HDACi 58 elagolix 58 BiovaxID 58 Ore Pharmaceuticals 58 registrational trials 58 TKM ApoB 58 Ofatumumab 58 oritavancin 58 antitumor activity 58 FTY# 58 milatuzumab 58 cabazitaxel 58 liposomal doxorubicin 58 Evoltra TM 58 multicenter Phase II 58 favorable pharmacokinetic profile 58 Zerenex 58 thrombopoietin 58 atrasentan 58 Epothilone D 58 betrixaban 58 Vaprisol 58 CTAP# Capsules 58 Quinamed 58 Rituximab 58 anti CD# antibodies 58 severe hypercholesterolemia 58 Anidulafungin 58 pivotal Phase III 58 IMiDs R 58 Randomized Phase 58 CLORETAZINE TM VNP#M 58 ApoB SNALP 58 TASQ 58 Xcellerated T Cells 58 lomitapide 58 Fodosine 58 Vernakalant 58 Indaflex TM 58 SERMs 58 phase Ib clinical 58 Ambrisentan 58 oral methylnaltrexone 58 Ceflatonin ® 58 alkylating agent 58 Phase IIb trial 58 fosbretabulin 58 PREOS 58 Relivar 58 rhThrombin 58 corticosteroid dexamethasone 58 Herceptin trastuzumab 58 Taxotere R 58 Telintra 58 platinum refractory 58 REMOXY ® 58 Oncaspar 58 MEND CABG 58 cetrorelix 58 ONCASPAR 58 ocular formulation 58 Xinlay 58 trastuzumab 58 oral salmon calcitonin 58 Reolysin 58 cintredekin besudotox 58 YONDELIS R 58 Entereg R 58 Phase III clinical trials 58 Temsirolimus 58 Phase 2a Clinical Trial 58 Hepatocellular Carcinoma HCC 58 dose escalation Phase 58 GGF2 58 UVIDEM 58 Oracea TM 58 ARIKACE 58 VELCADE 58 HGS ETR1 mapatumumab 58 vinca alkaloid 58 RITUXAN 58 Zelrix 58 NKTR 58 Onalta ™ 58 Phenoptin 58 Shigamabs R 58 atrial fibrillation budiodarone ATI 58 class mGluR5 inhibitor 58 siRNA therapeutics 58 imatinib Gleevec ® 58 NASDAQ LGND 58 Tamibarotene 58 HDAC inhibitor 58 EGFr 58 rFIXFc 58 ATL# [002] 58 candidate AQ4N 58 telbivudine 58 Phase 2a 58 Phase III Pivotal 58 tiuxetan 58 Octreolin 58 BENLYSTA ® 58 acute coronary syndromes ACS 58 Azilect ® 58 IND submission 58 tolerability pharmacokinetics 58 Molecular Insight 58 nucleoside analogs 58 4SC 58 follicular NHL 58 cutaneous T 58 GATTEX ® 58 ALK inhibitor 58 Allovectin 7 ® 58 Milatuzumab 58 BCR ABL inhibitors 58 bortezomib 58 Ecallantide 58 Clofarabine 58 Spiegelmer ® 58 Gleevec resistant 58 E2F Decoy 58 evaluating satraplatin 58 APEX PD 58 agonistic human 58 clofarabine 58 trastuzumab emtansine T DM1 58 NUVIGIL 58 novel histone deacetylase 58 Vectibix 58 ANA# 58 Epothilones 58 urocortin 2 58 PROMACTA 58 anti mitotic 58 relapsed ovarian cancer 58 Cintredekin Besudotox 58 Talabostat 58 alpha folate receptor 58 tremelimumab 58 recurrent glioblastoma multiforme 58 ISA# [002] 57 renin inhibitor 57 Phase 2a clinical 57 chemotherapeutics 57 GLP toxicology studies 57 TG# [001] 57 EZN 57 Betaferon ® 57 isavuconazole 57 BrachySil 57 Panzem NCD 57 HepeX B 57 metastatic HRPC 57 cetuximab 57 placebo controlled Phase 57 Excellarate 57 oral formulation 57 sipuleucel T 57 VEGF inhibitors 57 ITAX 57 ZADAXIN ® 57 nalbuphine ER 57 rhIL 7 57 Celsion Corporation 57 torezolid phosphate 57 AVASTIN 57 palifosfamide Zymafos TM 57 Phase IIb 57 resistant ovarian cancer 57 tubulin inhibitor 57 HSP# inhibitor 57 prostate cancer HRPC 57 2 methoxyestradiol 57 Vicriviroc 57 sunitinib 57 AZILECT R 57 temsirolimus 57 forodesine hydrochloride 57 Actilon 57 rALLy 57 crizotinib PF # 57 LY# [002] 57 Urocidin TM 57 IMiD 57 mTOR inhibition 57 dexanabinol 57 Ziopharm 57 PEGylated 57 T#I [002] 57 investigational pan BCR 57 unique alkylating agent 57 ALGRX 57 visilizumab 57 immunotherapeutic 57 YERVOY 57 EGFR inhibitors 57 peptidomimetic 57 compound AEZS 57 NovaDel 57 proteasome inhibitors 57 PROVENGE 57 PRIMO CABG 57 INCB# [003] 57 Trofex TM 57 SUCCEED trial 57 antithrombotic 57 Arixtra 57 Ridaforolimus